With the increasing prevalence of obesity‐associated metabolic and cardiovascular disorders, our study places the lipid kinase PIKfyve in the context of cardiometabolic diseases and highlights the therapeutic potential of PIKfyve pharmacological inhibition to limit mitochondrial damage and to improve cardiometabolic phenotype in obese patients. The gene discussed is PIKFYVE; the disease is cardiovascular disorder.